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Dear CLARITY committee, 
 
On behalf of the Omicia/University of Utah/InVitae, (OUI) team, we would like to 
describe our approach to this challenge, our workflow and reports. We have provided an 
executive summary and a detailed report for each family. The executive summary 
includes the findings and clinical recommendations. The detailed reports show the data 
for each test with supporting evidence and some technical interpretation. In this 
document we provide an overview of our team and our analysis strategy.  
 
Our team is composed of three groups: one academic and two commercial. The OUI team 
includes physicians, geneticists, bioinformaticians, computational biologists, and 
software engineers. Two systems have been at the core of our analyses: The Omicia 
OpalTM platform and the InVitae genetic test of known inherited conditions powered by 
LocusDev. Both tools have been central to our analyses, and we have generated clinical 
laboratory-like reports from both systems. The data provided by the organizers have been 
used as is assuming that the variants are all called correctly. As you can see in the Opal 
report, we have tried to assess the data quality, but only at a very high level, given that 
data generation and variant calling has been out of our control, so a detailed sensitivity 
and specificity analysis was not possible. 
 
Opal is a clinical decision support tool that assists in the clinical interpretation of 
genomes and empowers clinical diagnostics by allowing users to identify a very short list 
of candidate disease-genes and variants of relevance to the disease and phenotype of the 
patient. Opal accomplishes this by automatically embedding the contents of patient 
variant files in a rich analysis environment, providing links to additional genome 
annotations, clinical variants from well-established pathogenic variant databases such as 
OMIM and HGMD, and literature cross-references for candidate disease genes and 
variants, and other resources. Most of the interactive analysis and result inspection has 
been performed with Opal, which is a web application system. Data and analyses were 
securely stored, accessed, shared and discussed by the team during the analysis of the 
project, while each team member had a secure, user controlled access to the genome and 
the analyses results and was able to share their results online. 
 
In summary, our analysis strategy was four-pronged: 
 
Test 1. Genome-wide ab initio searches using VAAST. VAAST is a new-in-class, rapid 
probabilistic search tool for identifying damaged genes and their disease-causing variants 
in personal genome sequences, using population data and amino acid substitution 
Results	  from	  Exome	  and	  WGS	  requires	  
both	  AnalyGc	  and	  Clinical	  Validity	  
•  AnalyGcal	  Validity:	  the	  test	  is	  accurate	  with	  
high	  sensiGvity	  and	  speciﬁcity.	  
•  Clinical	  Validity:	  Given	  an	  accurate	  test	  result,	  
what	  impact	  and/or	  outcome	  does	  this	  have	  
on	  the	  individual	  person?	  





•  Minimal	  Standard:	  exomes	  and	  genomes	  ought	  to	  be	  
performed	  in	  a	  CLIA-­‐cerGﬁed	  environment	  for	  germline	  
genomic	  DNA	  from	  live	  humans	  .	  
•  Easier	  said	  than	  done	  in	  academia,	  but	  some	  companies	  oﬀer	  
this	  now:	  Illumina,	  23andMe,	  Ambry	  GeneGcs,	  and	  some	  
academic	  places	  do	  oﬀer	  this	  now:	  UCLA,	  Baylor,	  Emory	  and	  
WashU	  for	  exomes.	  
	  
CLIA-­‐cerGﬁed	  exomes	  and	  WGS	  
•  The	  CLIA-­‐cerGﬁed	  pipelines	  aZempt	  to	  
minimize	  false	  posiGves	  with	  increased	  depth	  
of	  sequencing,	  although	  there	  can	  sGll	  be	  
many	  no-­‐calls	  and	  other	  areas	  of	  uncertainty,	  
which	  should	  be	  reported	  as	  No-­‐Call	  Regions.	  	  
•  This	  will	  minimize	  false	  posiGves	  and	  also	  tend	  
to	  prevent	  false	  negaGves.	  
Discov	  Med.	  2011	  Jul;12(62):41-­‐55.	  
Exome	  sequencing	  of	  one	  pedigree	  in	  
a	  research	  sedng.	  
Figure 1. The pedigree structure is shown, with corresponding ID 
numbers. The three subjects in the pedigree affected with ADHD are 
shaded. Only 84060 has the idiopathic hemolytic anemia. The mother, 
father and two sons were sequenced. The two sisters in the family 
declined to participate in the study, thus their phenotype status is 
unknown and marked as “?”. 
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BioinformaGcs	  Analysis	  for	  ADHD	  
pedigree	  
Poor concordance: Intersection of variants. We show here the 
variants identified by the three main pipelines as being present in 
the three males with ADHD, but not present in the unaffected 
mother.   
	  
	  
Filtering	  Steps	  for	  ADHD	  Shared variants: 13786 
SNPs+ 123 indels 
Gene-­‐based	  annotaGon	  to	  idenGfy	  non-­‐
synonymous	  or	  frameshie	  variants	  
 3775 variants 
Conserved	  variants	  from	  44-­‐species	  
alignment	  
 1694 variants 
Remove	  variants	  in	  segmental	  
duplicaGon	  regions	  
 1551 variants 
Remove	  variants	  found	  in	  1000	  
Genomes	  Project	  CEU	  populaGon	  
 107 variants 
Remove	  variants	  found	  in	  1000	  
Genomes	  Project	  YRI	  populaGon	  
 105 variants 
Remove	  variants	  found	  in	  1000	  
Genomes	  Project	  CHB+JPT	  
populaGon	  105 variants 
Remove	  variants	  found	  in	  dbSNP	  130	  
Dominant	  model	  
 41 variants 
Literature survey 











filtering out variants 





Supplementary Table 6. Validated variants for ADHD and their population frequency in 5,680 and ~600 deep-sequenced exomes  




























































% in BGI 
exomes 
# variants in 
~600 Baylor 
exomes 




A G ABCA8 Nonsynonymous C1387R 0 0.0% 0 0.0% 
chr11 68566802 
 
G A CPT1A Nonsynonymous L193F 0 0.0% 0 0.0% 
chr8 100994274 
 
A G RGS22 Nonsynonymous I1084T 0 0.0% 0 0.0% 
chr18 61654247 
 
G T SERPINB8 Nonsynonymous G287V 0 0.0% 0 0.0% 
chr1 207200877 
 
- T C1orf116 frameshift insertion  34 1.4% 0 0.0% 
chr18 29101156 
 
T G DSG2 Nonsynonymous V158G 1 0.0% 1 0.2% 
chr3 125877290 
 
G A ALDH1L1 Nonsynonymous P107L 2 0.0% 0 0.0% 
chr13 52542680 
 
A G ATP7B Nonsynonymous V536A 1 0.0% 1 0.2% 
chr10 53458646 
 
A C CSTF2T Nonsynonymous C222G 4 0.1% 1 0.2% 
chr14 21972019 
 
G A METTL3 Nonsynonymous R36W 9 0.2% 1 0.2% 
chr11 76954790 
 
- A GDPD4 frameshift insertion  36 1.5% 6 1.0% 
chr7 87160618 
 
A T ABCB1 Nonsynonymous S893T 815 14.3%1 9 1.5% 
chr11 134128923 
 
C G ACAD8 Nonsynonymous S171C 112 2.0% 20 3.3% 
chr20 17956347 
 
C T C20orf72 Nonsynonymous R178W 23 0.4% 8 1.3% 
chr8 33318891 
 
T C FUT10 Nonsynonymous Q27R 15 0.3% 3 0.5% 
chr13 20797025 
 
A T GJB6 Nonsynonymous S199T 68 1.2% 4 0.7% 
chr16 71015329 
 
G T HYDIN Nonsynonymous P1491H 77 1.4% dozens >5.0% 
chr10 22019855 
 
G A MLLT10 Nonsynonymous R713H 15 0.3% 6 1.0% 
chr17 10415269 
 
A G MYH1 Nonsynonymous Y435H 99 1.7% 14 2.3% 
chr1 145015877 
 
G T PDE4DIP Nonsynonymous L142I 1256 22.1% hundreds >30.0% 
chr2 98809432 
 
T C VWA3B Nonsynonymous I513T 15 0.3% 16 2.7% 
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chr5 115202418 AAGA - AP3S1 frameshift deletion  185 7.8% 19 3.2% 
OpGmizing	  Variant	  Calling	  in	  Exomes	  at	  
BGI	  in	  2011	  
•  Agilent	  v2	  44	  MB	  exome	  kit	  
•  Illumina	  Hi-­‐Seq	  for	  sequencing.	  
•  Average	  coverage	  ~100-­‐150x.	  
•  Depth	  of	  sequencing	  of	  >80%	  of	  the	  target	  
region	  with	  >20	  reads	  or	  more	  per	  base	  pair.	  
•  Comparing	  various	  pipelines	  for	  alignment	  and	  
variant-­‐calling.	  
2-­‐3	  rounds	  of	  sequencing	  at	  BGI	  to	  aDain	  
goal	  of	  >80%	  of	  target	  region	  at	  >20	  reads	  
per	  base	  pair	  
Exome Capture Statistics K24510-84060 K24510-92157-a K24510-84615 K24510-88962 
Target region (bp) 46,401,121  46,401,121  46,401,121  46,257,379  
Raw reads 138,779,950  161,898,170  156,985,870  104,423,704  
Raw data yield (Mb) 12,490  14,571  14,129  9,398  
Reads mapped to genome 110,160,277  135,603,094  135,087,576  83,942,646  
Reads mapped to target region 68,042,793  84,379,239  80,347,146  61,207,116  
Data mapped to target region (Mb) 5,337.69  6,647.18  6,280.01  4,614.47  
Mean depth of target region 115.03 143.25 135.34 99.76 
Coverage of target region (%) 0.9948  0.9947  0.9954  0.9828  
Average read length (bp) 89.91  89.92  89.95  89.75  
Fraction of target covered >=4X 98.17  98.38  98.47  94.25  
Fraction of target covered >=10X 95.18  95.90  95.97  87.90  
Fraction of target covered >=20X 90.12  91.62  91.75  80.70  
Fraction of target covered >=30X 84.98  87.42  87.67  74.69  
Capture specificity (%) 61.52  62.12  59.25  73.16  
Fraction of unique mapped bases on or near target 65.59  65.98  63.69  85.46  
Gender test result M M M F 
Depth	  of	  Coverage	  in	  15	  exomes	  >	  20	  






















Deep	  Exome	  sequencing	  
Fig.1	  CorrelaGon	  between	  the	  percentage	  of	  target	  regions	  covered	  and	  the	  sequencing	  
depth	  in	  human	  exome	  sequencing.	  Take	  >=30X	  series	  (the	  purple	  line)	  for	  example:	  when	  
the	  sequencing	  depth	  is	  30X,	  only	  half	  of	  the	  target	  regions	  (51%)	  are	  covered	  at	  above	  30X.	  
While	  at	  the	  100X	  and	  200X	  sequencing	  depths,	  a	  much	  higher	  percentage	  (81%	  and	  90%,	  
respecGvely)	  of	  the	  target	  regions	  is	  covered	  at	  above	  30X.	  	  	  




GWAS	  has	  staGsGcal	  rigor	  with	  a	  
threshold	  p	  value	  
•  Should	  exome	  sequencing	  also	  have	  a	  
threshold	  level	  of	  rigor,	  such	  as	  >80%	  of	  target	  
region	  with	  20	  reads	  or	  more	  per	  base	  pair?	  
•  This	  is	  accepted	  pracGce	  at	  major	  genome	  
sequencing	  centers	  (Baylor,	  WashU,	  Broad),	  
but	  apparently	  not	  everywhere	  else….	  
Shouldn’t	  this	  be	  required?	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Pipelines	  Used	  on	  Same	  Set	  of	  Seq	  Data	  by	  Diﬀerent	  
Analysts,	  using	  Hg19	  Reference	  Genome	  
1)  BWA	  -­‐	  Sam	  format	  to	  Bam	  format	  -­‐	  Picard	  to	  remove	  duplicates	  -­‐	  GATK	  (version	  
1.5)	  with	  recommended	  parameters	  	  (GATK	  IndelRealigner,	  base	  quality	  scores	  
were	  re-­‐calibrated	  by	  GATK	  Table	  RecalibraGon	  tool.	  Genotypes	  called	  by	  GATK	  
UniﬁedGenotyper.	  	  
	  
2)  BWA	  -­‐	  Sam	  format	  to	  Bam	  format-­‐Picard	  to	  remove	  duplicates	  -­‐	  SamTools	  version	  
0.1.18	  to	  generate	  genotype	  calls	  	  -­‐-­‐	  The	  “mpileup”	  command	  in	  SamTools	  were	  
used	  for	  idenGfy	  SNPs	  and	  indels.	  
	  
3)  SOAP-­‐Align	  –	  SOAPsnp	  –	  then	  BWA-­‐SOAPindel	  (adopts	  local	  assembly	  based	  on	  an	  
extended	  de	  Bruijn	  graph	  )	  
	  
4)  GNUMAP-­‐SNP	  (probabilisGc	  Pair-­‐Hidden	  Markov	  which	  eﬀecGvely	  accounts	  for	  
uncertainty	  in	  the	  read	  calls	  as	  well	  as	  read	  mapping	  in	  an	  unbiased	  fashion)	  
	  
5)  BWA	  -­‐	  Sam	  format	  to	  Bam	  format	  -­‐	  Picard	  to	  remove	  duplicates	  -­‐	  SNVer	  	  
6)  BWA	  -­‐	  Sam	  format	  to	  Bam	  format	  -­‐	  Picard	  to	  remove	  duplicates	  -­‐	  SCALPEL	  
Total	  SNVs
Mean	  #	  of	  total	  SNVs	  across	  15	  exomes,	  called	  by	  5	  pipelines.	  The	  percentage	  
in	  the	  center	  of	  the	  the	  Venn	  diagram(Parenthesis)	  is	  the	  percent	  of	  total	  SNVs	  
called	  by	  all	  ﬁve	  pipelines.	  	  
A)	  

B)	  Mean	  #	  of	  known	  SNVs	  (present	  in	  dbSNP135)	  found	  by	  5	  pipelines	  across	  
15	  exomes.	  The	  percentage	  in	  the	  center	  of	  the	  the	  Venn	  diagram	  is	  the	  
percent	  of	  known	  SNVs	  called	  by	  all	  ﬁve	  pipelines.	  	  
B)	  
Known	  SNVs	  
•  C)	  Mean	  #	  of	  novel	  SNVs	  (not	  present	  in	  dbSNP135)	  found	  by	  5	  pipelines	  across	  15	  
exomes.	  The	  percentage	  in	  the	  center	  of	  the	  Venn	  diagram	  is	  the	  percent	  of	  novel	  
SNVs	  called	  by	  all	  ﬁve	  pipelines.	  
C)	  
Novel	  SNVs	  
Comparing	  the	  concordance	  among	  the	  5	  
pipelines	  used	  to	  analyze	  Illumina	  data,	  also	  
stra^ﬁed	  by	  read	  depth	  from	  >0	  to	  >30	  reads.	  
Total	  mean	  overlap,	  plus	  or	  minus	  one	  standard	  devia^on,	  observed	  between	  three	  
indel	  calling	  pipelines:	  GATK,	  SOAP-­‐indel,	  and	  SAMTools.	  	  a)	  Mean	  overlap	  when	  indel	  
posiGon	  was	  the	  only	  necessary	  agreement	  criterion.	  b)	  Mean	  overlap	  when	  indel	  
posiGon,	  base	  length	  and	  base	  composiGon	  were	  the	  necessary	  agreement	  criteria.	  	  	  
Indels-­‐	  Overlap	  by	  Base	  	  
PosiGon	  only	  
Indels-­‐	  Overlap	  by	  Base	  	  
PosiGon,	  Length	  and	  ComposiGon	  
INDELS	  
Tools	  sensiGvity	  for	  longer	  indels	  
•  Standard	  read	  mapping	  and	  scanning	  algorithms,	  
such	  as	  BWA,	  GATK,	  and	  SAMTools,	  are	  suitable	  
for	  detecGng	  mutaGons	  only	  for	  a	  few	  
nucleoGdes.	  
	  
–  The	  sensiGvity	  drops	  signiﬁcantly	  for	  indels	  larger	  than	  
10bp	  
–  Large	  inserGons	  (>	  read	  length),	  are	  hard	  to	  detect.	  
–  As	  a	  result,	  variants	  >	  15	  bp	  have	  rarely	  been	  reported	  
in	  exome	  studies	  
Gavin	  R.	  Oliver,	  F1000	  Research,	  2012	  
To	  conclude,	  results	  from	  Exome	  and	  WGS	  
requires	  both	  Analy^c	  and	  Clinical	  Validity	  
•  AnalyGcal	  Validity:	  the	  test	  is	  accurate	  with	  
high	  sensiGvity	  and	  speciﬁcity.	  
•  Clinical	  Validity:	  Given	  an	  accurate	  test	  result,	  
what	  impact	  and/or	  outcome	  does	  this	  have	  
on	  the	  individual	  person.	  






Figure 4. NAT activity of recombinant hNaa10p WT or p.Ser37Pro 
towards synthetic N-terminal peptides. A) and B) Purified MBP-hNaa10p 
WT or p.Ser37Pro were mixed with the indicated oligopeptide substrates (200 
µM for SESSS and 250 µM for DDDIA) and saturated levels of acetyl-CoA 
(400 µM). Aliquots were collected at indicated time points and the acetylation 
reactions were quantified using reverse phase HPLC peptide separation. 
Error bars indicate the standard deviation based on three independent 
experiments. The five first amino acids in the peptides are indicated, for 
further details see materials and methods. Time dependent acetylation 
reactions were performed to determine initial velocity conditions when 
comparing the WT and Ser37Pro NAT-activities towards different 
oligopeptides. C) Purified MBP-hNaa10p WT or p.Ser37Pro were mixed with 
the indicated oligopeptide substrates (200 µM for SESSS and AVFAD, and 
250 µM for DDDIA and EEEIA) and saturated levels of acetyl-CoA (400 µM) 
and incubated for 15 minutes (DDDIA and EEEIA) or 20 minutes (SESSS and 
AVFAD), at 37°C in acetylation buffer. The acetylation activity was determined 
as above. Error bars indicate the standard deviation based on three 
independent experiments. Black bars indicate the acetylation capacity of the 
MBP-hNaa10p wild type (WT), while white bars indicate the acetylation 
capacity of the MBP-hNaa10p mutant p.Ser37Pro. The five first amino acids 
in the peptides are indicated. 
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